Lilly says Phase 1 study shows type II JAK2 inhibitor cuts spleen volume in previously treated myelofibrosis patients

Eli Lilly and Company

Eli Lilly and Company

LLY

0.00
  • Eli Lilly disclosed early Phase 1 results for AJ1-11095, a first-in-class type II JAK2 inhibitor for previously treated myelofibrosis.
  • Results will be presented at the European Hematology Association Annual Meeting in 2026, with an oral session scheduled in Stockholm.
  • The study showed encouraging safety with signs of clinical benefit, including reduced spleen enlargement, improved symptoms, and evidence of disease-burden decline.
  • Lilly is running a second-line expansion cohort, with plans to study the drug in high-risk polycythemia vera and in JAK-inhibitor-naive myelofibrosis.
  • The program entered Lilly’s pipeline following its acquisition of Ajax Therapeutics, positioning the asset as a potential next-line option in myelofibrosis.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Eli Lilly and Company published the original content used to generate this news brief via PR Newswire (Ref. ID: 202606131115PR_NEWS_USPR_____DE81773) on June 13, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.